![sglt-2_inhibitors [TUSOM | Pharmwiki]](https://tmedweb.tulane.edu/pharmwiki/lib/exe/fetch.php/sglt2.png "sglt-2_inhibitors [TUSOM | Pharmwiki]")
sglt-2_inhibitors [TUSOM | Pharmwiki]
SciELO - Brasil - SGLT-2 inhibitors in diabetes: a focus on renoprotection SGLT-2 inhibitors in diabetes: a focus on renoprotection
The mechanism of SGLT2 inhibition in glucose control - PACE-CME
Cardiac substrate utilization in heart failure: Where is the relevance of SGLT2 inhibition? - The Journal of Thoracic and Cardiovascular Surgery
Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics
Sodium-glucose cotransporter-2 inhibitors: Understanding the mechanisms for therapeutic promise and persisting risks - ScienceDirect
SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control | Nature Reviews Cardiology
A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity - Journal of Cardiology
Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 ( SGLT2) Inhibitors: A State-of-the-Art Review | JACC: Basic to Translational Science
SGLT2 Inhibition in the Diabetic Kidney—From Mechanisms to Clinical Outcome | American Society of Nephrology
Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: from biomarkers to clinical outcomes in heart failure and diabetic kidney disease - Metabolism - Clinical and Experimental
The potential role and rationale for treatment of heart failure with sodium–glucose co‐transporter 2 inhibitors - Butler - 2017 - European Journal of Heart Failure - Wiley Online Library
Glucose-lowering mechanism of SGLT2 inhibitors. Source: Fioretto et al.... | Download Scientific Diagram
Frontiers | Effect of Sodium-Glucose Co-transporter 2 Inhibitors on Bone Metabolism and Fracture Risk | Pharmacology
SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetes. | Semantic Scholar
Sodium-glucose cotransporter-2 inhibitors: Understanding the mechanisms for therapeutic promise and persisting risks - Journal of Biological Chemistry
SGLT2 Inhibitors and nephroprotection in diabetic kidney disease: From mechanisms of action to the latest evidence in the literature
IJMS | Free Full-Text | SGLT2is and Renal Protection: From Biological Mechanisms to Real-World Clinical Benefits | HTML
SGLT2 Inhibitors - Pharmacology Summary Mechanisms ... | GrepMed
Mechanisms of SGLT2 (Sodium-Glucose Transporter Type 2) Inhibition-Induced Relaxation in Arteries From Human Visceral Adipose Tissue | Hypertension
Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 ( SGLT2) Inhibitors | Semantic Scholar
Renoprotective effects of sodium-glucose cotransporter-2 inhibitors - Kidney International
Potential Mechanisms of Sodium-Glucose Co-Transporter 2 Inhibitor-Related Cardiovascular Benefits - The American Journal of Medicine
SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control | Nature Reviews Cardiology
Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review | Journal of the American College of Cardiology
The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial -
